Uricosuric Effect of an Anticholinergic Agent in Hyperuricemic Subjects

1974 ◽  
pp. 769-776 ◽  
Author(s):  
A. E. Postlethwaite ◽  
C. M. Ramsdell ◽  
W. N. Kelley
Keyword(s):  
Anticholinergic Agent ◽  
Uricosuric Effect

Teriflunomide‐associated urolithiasis: a new adverse reaction explained by its uricosuric effect

2021 ◽  
Author(s):  
Bérenger Largeau ◽  
Frédéric Béra ◽  
Jacques Vannier ◽  
Annie‐Pierre Jonville‐Béra
Keyword(s):  
Adverse Reaction ◽  
Uricosuric Effect

Suppression of Sleep-Induced Growth Hormone Secretion by Anticholinergic Agent Abolishes Dawn Phenomenon

Diabetes ◽  
1988 ◽  
Vol 37 (2) ◽  
pp. 166-171 ◽  
Author(s):  
M. B. Davidson ◽  
M. D. Harris ◽  
F. H. Ziel ◽  
C. S. Rosenberg
Keyword(s):  
Growth Hormone ◽  
Hormone Secretion ◽  
Growth Hormone Secretion ◽  
Anticholinergic Agent ◽  
Dawn Phenomenon

Inhibition of probenecid uricosuria by pyrazinamide and para-aminohippurate

1977 ◽  
Vol 232 (3) ◽  
pp. F222-F226
Author(s):  
A. D. Meisel ◽  
H. S. Diamond
Keyword(s):  
Uricosuric Effect ◽  
Male Subjects ◽  
Urate Secretion

Both para-aminohippurate (PAH) and pyrazinamide inhibited the uricosuric response to probenecid administration. The mechanism of this inhibition of probenecid uricosuria was assessed in 18 male subjects. The decrease in uricosuria was assessed in 18 male subjects. The decrease in uricosuric response to probenecid observed after pyrazinamide administration or PAH infusion occurs by different mechanisms. Administration of PAH and probenecid together resulted in reduced excretion of both drugs. PAH was weakly uricosuric and did not appear to inhibit urate secretion. PAH inhibition of probenecid uricosuria is accounted for by inhibition of probenecid secretion. Probenecid excretion was not affected by pyrazinamide administration. Inhibition of probenecid-induced uricosuria by pyrazinamide is most likely due to inhibition of urate secretion. The urate secretory carrier inhibited by pyrazinamide appears to be independent of that responsible for secretion of probenecid and PAH. Probenecid secretion appears to be required for its uricosuric effect.

scholarly journals Acute bronchodilator responses to β2-agonist and anticholinergic agent in COPD: Their different associations with exacerbation

2017 ◽  
Vol 127 ◽  
pp. 14-20 ◽  
Author(s):  
Satoshi Konno ◽  
Hironi Makita ◽  
Masaru Suzuki ◽  
Kaoruko Shimizu ◽  
Hirokazu Kimura ◽  
...  
Keyword(s):  
Anticholinergic Agent ◽  
Β2 Agonist

Comparison of the Effects of Inhaled SCH 1000 and Fenoterol on Exercise-Induced Bronchospasm in Children

PEDIATRICS ◽  
1980 ◽  
Vol 66 (1) ◽  
pp. 109-114
Author(s):  
R. Yeung ◽  
G. M. Nolan ◽  
H. Levison
Keyword(s):  
Side Effects ◽  
Pulmonary Function ◽  
Controlled Study ◽  
Anticholinergic Drugs ◽  
Base Line ◽  
Anticholinergic Agent ◽  
Asthmatic Children ◽  
Before And After ◽  
Exercise Induced ◽  
Better Than

The effect of 40 µg of SCH 1000 (ipratropium bromide, an anticholinergic agent) on bronchodilation and suppression of exercise-induced bronchospasm (EIB) was compared with 400 µg of fenoterol and a placebo in a single-blind controlled study. Twenty-seven randomly selected asthmatic children performed a standardized treadmill exercise challenge and the 17 children who were shown to have EIB continued in the study. Pulmonary function was evaluated before and after drug administration and exercise. When individual results were analyzed and grouped according to the responsiveness of EIB to the drugs, two patterns emerged: (1) the EIB was more severe in those (6/17) children who did not respond to either drug than in the rest of the children; (2) the resting pulmonary function was significantly better in the children (4/17) who responded to both drugs than in those (7/17) who responded to fenoterol alone. In conclusion SCH 1000 was shown to be an effective bronchodilator comparable to, but no better than, fenoterol. It had minimal side effects. As an EIB inhibitor it depended on relatively normal base line pulmonary function and only a moderate deterioration following exercise, whereas fenoterol depended on the exercise response alone. Although anticholinergic drugs are not very extensively used, SCH 1000 may be useful in some patients where the β2 adrenergic drugs cause significant side effects or are contraindicated.

Sign in / Sign up

Export Citation Format

Share Document